Ozempic copies restricted after US judge denies injunction
(Reuters) -A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records show.
The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration's decision that there was no longer a shortage of the medicines' active ingredient, semaglutide.
Compounders had been allowed to produce hundreds of thousands of doses of copies of Novo's obesity and diabetes drugs only while the FDA said they were in short supply. Many of these are sold by large telehealth companies like Hims & Hers.
U.S. District Judge Mark Pittman in Texas denied compounders' bid for a preliminary injunction, according to the court docket. Pittman filed his legal reasoning under seal, but by denying the injunction request, a May timeline set by the FDA for when large U.S. compounders will have to exit the market remains in place.
It also follows a decision the judge made earlier this year refusing to allow compounding pharmacies to keep making copies of Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro.
The FDA and Novo Nordisk did not immediately respond to requests for comment.
Lee Rosebush, chairman of lead plaintiff Outsourcing Facilities Association, told Reuters that his organization had presented evidence of an ongoing semaglutide shortage that was obtained after the lawsuit was filed. However, Rosebush said the judge declined to consider it, finding that it was filed late.
The FDA had said it would not take any enforcement action against compounders before the court ruled.
The regulator has given larger so-called outsourcing facilities, which make compounded drugs in bulk and are regulated by the agency, until May 22. Smaller compounding pharmacies, which make drugs to fill prescriptions for individual patients and are primarily overseen by U.S. states, must immediately cease making copies of semaglutide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Compliance Group Inc. and Loftware Announce Strategic Partnership to Drive Digital Labeling Transformation in Life Sciences
CHICAGO--(BUSINESS WIRE)--Compliance Group Inc., a premier validation, regulatory consulting firm serving the Life sciences industry, is thrilled to announce its strategic partnership with Loftware, a global leader in product identification and supply chain transparency. Purpose-Driven Partnership for a Compliant, Scalable Future Loftware's powerful, cloud-enabled labeling technology with CG's deep labeling expertise and proven Computer Software Assurance (CSA) aligned validation strategies, the partnership delivers: World class labeling consulting & End-to-end support Insights into inefficiencies and compliance gaps in legacy systems Expert guidance on system migration & architecture alignment FDA, MDR, Global ISO compliant validation (IQ, OQ, PQ) Integration with enterprise systems (SAP, Oracle, Veeva, etc.) Real-World Impact: Leading Global MedTech Transformation A global leader in medical devices selected CG to lead the replacement of their Global Labeling System (GLS). Our team conducted: Thorough assessment of legacy system Vendor selection & Loftware readiness planning Define requirements with expert consulting Validation aligned with CSA, FDA, & Global ISO standards Full implementation with audit readiness Executive Perspectives "Our partnership with Loftware reinforces our commitment to helping clients build innovative, scalable, and compliant labeling systems. With our AI powered design validation approach, we enable life sciences companies to move faster while staying inspection ready.' added Sarat Bhamidipati, CEO, Compliance Group Inc. "We're excited to partner with Compliance Group to help life sciences organizations modernize their labeling environments while meeting the industry's rigorous regulatory requirements. By combining our cloud-based labeling solutions with Compliance Group's deep validation and regulatory expertise, we're enabling companies to accelerate digital transformation, reduce risk, and ensure long-term compliance," added Carter Johnson, Vice President, Global Alliance Sales at Loftware. About Compliance Group Inc. CG is a leading consulting & validation partner for the Life sciences industry. Our experts bring decades of regulatory experience & specialize in validation, label consulting, and digital transformation. With a vendor-neutral, AI-driven approach, we use people, platforms, and processes to build a compliant, scalable quality system. Learn more at About Loftware Loftware is the global leader in product identification, artwork management, and connected packaging. Our cloud-based solutions power real-time collaboration, ensure compliance, improve authenticity, and deliver supply chain visibility from product development to consumer engagement. We provide scalable, data-driven labeling and packaging technologies that help companies boost speed to market, enhance efficiency, and connect physical products to digital experiences. Trusted by global brands and backed by over 40 years of innovation, Loftware supports customers across industries with offices in the US, UK, Slovenia, China, and Singapore. Learn more at
Newsweek
26 minutes ago
- Newsweek
FDA Issues Risk Warning for Nationwide Cough Syrup Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of cough syrup due to potential bacterial contamination has been issued the second-highest risk warning by the U.S. Food and Drug Administration (FDA). Prestige Consumer Healthcare Inc., based in New York, issued a voluntary recall for more than 10,000 cases of its honey cough syrup on June 17 because they may have been spoiled by the bacterium Bacillus cereus. The FDA subsequently issued a Class II risk warning for the recall on July 11. Newsweek contacted Prestige Consumer Healthcare Inc. for comment by email outside of regular working hours. Prestige Consumer Healthcare Inc. issued a voluntary recall for more than 10,000 cases of its honey cough syrup on June 17, 2025. Prestige Consumer Healthcare Inc. issued a voluntary recall for more than 10,000 cases of its honey cough syrup on June 17, 2025. Heiko Wolfraum/picture-alliance/dpa/AP Images Why It Matters A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. The FDA warned in its recall notice that Bacillus cereus may lead to two forms of food-borne illnesses. The first can cause symptoms including nausea, vomiting and stomach cramps that typically develop between one and six hours after consuming contaminated food. The second form of illness often causes stomach cramps and diarrhea that start between eight and 16 hours after consuming the contaminated product. The FDA added: "Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death." What To Know The product affected by the recall is Little Remedies Honey Cough Syrup - UPC code: 7-56184-10737-9 - Lot codes: 0039 / 0545 / 0640 / 0450 / 1198 - expiry dates: 11/2025 / 01/2026 / 02/2026 / 05/2026 / 12/2026. A total of 245,352 units are impacted by the recall, and they were distributed nationwide to retailers and online from 12/14/2022 to 06/04/2025. The recall does not include other Little Remedies products, the agency said. As of June 18, no illnesses had been reported in connection to the consumption of the affected product. What People Are Saying The FDA, in a report: "Bacillus cereus is an aerobic spore-forming bacterium that is commonly found in soil, on vegetables, and in many raw and processed foods. B. cereus food poisoning may occur when foods are prepared and held without adequate refrigeration for several hours before serving, with B. cereus reaching >106 cells/g. Foods incriminated in past outbreaks include cooked meat and vegetables, boiled or fried rice, vanilla sauce, custards, soups, and raw vegetable sprouts." The FDA, in its alert: "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax." What Happens Next The recall is listed as ongoing, according to the FDA. Consumers who are in possession of the recalled cough syrup should stop using it immediately and contact their health care provider if they experience any symptoms related to the use of it, the FDA said. The company will offer refunds to consumers who bought the product from the recalled lots.
Wall Street Journal
26 minutes ago
- Wall Street Journal
FDA Authorizes Juul E-Cigarettes
Juul Labs has won authorization from federal regulars for its e-cigarettes to remain on the U.S. market, according to people familiar with the matter. The decision breathes new life into the vaping company after a federal ban in 2022 pushed it to the brink of bankruptcy. The Food and Drug Administration has authorized Juul's original vaporizer, along with refill cartridges in tobacco and menthol flavors, the people familiar with the matter said.
